Desjardins initiated coverage on IM Cannabis with a new price target
$IMCC
Medicinal Chemicals and Botanical Products
Health Care
Desjardins initiated coverage of IM Cannabis with a rating of Buy and set a new price target of $10.50
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/5/2021 | $8.00 | Buy | ROTH Capital |
| 7/14/2021 | Buy | Desjardins | |
| 7/14/2021 | $10.50 | Buy | Desjardins |
ROTH Capital initiated coverage of IM Cannabis with a rating of Buy and set a new price target of $8.00
Desjardins initiated coverage of IMC Mortgage Co with a rating of Buy
Desjardins initiated coverage of IM Cannabis with a rating of Buy and set a new price target of $10.50
TORONTO and GLIL YAM, Israel, Jan. 5, 2026 /PRNewswire/ -- IM Cannabis Corp. ("IMC" or the "Company") (NASDAQ:IMCC), medical cannabis company with operations in Israel and Germany, announced today that Mr. Alon Dayan has been appointed to the Company's board of directors effective December 31, 2025. Mr. Dayan, who is currently the Chief Executive Officer of KeepZone AI Inc., a position he has held since 2025, brings over 15 years of executive experience in the homeland security technology sector, with a proven track record of founding and scaling innovative companies focused on systems integration, secure communications, and international business development. As the founder and Chief Execu
Engages Exclusive Financial Advisors for U.S. Opportunities and Potential Divestitures of German and Israeli Operations TORONTO and GLIL YAM, Israel, Dec. 30, 2025 /PRNewswire/ -- IM Cannabis Corp. ("IMC" or the "Company") (NASDAQ:IMCC), medical cannabis company with operations in Israel and Germany, today announced that it is actively evaluating certain strategic opportunities to expand its operations into the United States cannabis market. This initiative follows President Donald Trump's executive order signed on December 18, 2025, which directs the Attorney General to expedite the rescheduling of marijuana from Schedule I to Schedule III under the Controlled Substances Act, recognizing it
TORONTO and GLIL YAM, Israel, Dec. 12, 2025 /PRNewswire/ -- IM Cannabis Corp. ("IMC" or the "Company") (NASDAQ:IMCC), a leading medical cannabis company with operations in Israel and Germany, today announced, further to its press release dated October 29, 2025, the appointment of Asi Levi, CPA, as the Company's Chief Financial Officer ("CFO"), effective immediately, to replace Uri Birenberg. Mr. Levi has over 15 years of experience in finance and controlling roles, including serving as Chief Financial Officer of Water Ways Technologies Inc. and DekelOil CI, part of Dekel Agri-Vision Plc and as Controller of SciSparc Ltd. and A2Z Cust2Mate Solutions Corp. He has overseen fundraising efforts
6-K - IM Cannabis Corp. (0001792030) (Filer)
6-K - IM Cannabis Corp. (0001792030) (Filer)
6-K - IM Cannabis Corp. (0001792030) (Filer)
TORONTO and GLIL YAM, Israel, Jan. 5, 2026 /PRNewswire/ -- IM Cannabis Corp. ("IMC" or the "Company") (NASDAQ:IMCC), medical cannabis company with operations in Israel and Germany, announced today that Mr. Alon Dayan has been appointed to the Company's board of directors effective December 31, 2025. Mr. Dayan, who is currently the Chief Executive Officer of KeepZone AI Inc., a position he has held since 2025, brings over 15 years of executive experience in the homeland security technology sector, with a proven track record of founding and scaling innovative companies focused on systems integration, secure communications, and international business development. As the founder and Chief Execu
TORONTO and GLIL YAM, Israel, Dec. 12, 2025 /PRNewswire/ -- IM Cannabis Corp. ("IMC" or the "Company") (NASDAQ:IMCC), a leading medical cannabis company with operations in Israel and Germany, today announced, further to its press release dated October 29, 2025, the appointment of Asi Levi, CPA, as the Company's Chief Financial Officer ("CFO"), effective immediately, to replace Uri Birenberg. Mr. Levi has over 15 years of experience in finance and controlling roles, including serving as Chief Financial Officer of Water Ways Technologies Inc. and DekelOil CI, part of Dekel Agri-Vision Plc and as Controller of SciSparc Ltd. and A2Z Cust2Mate Solutions Corp. He has overseen fundraising efforts
TORONTO and GLIL YAM, Israel, Sept. 11, 2024 /PRNewswire/ -- IM Cannabis Corp. ("IMC" or the "Company") (NASDAQ:IMCC) (CSE:IMCC), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that Mr. Shmulik Arbel has been appointed to the Company's board of directors (the "Board") effective September 9, 2024. Mr. Arbel brings a wealth of experience in strategic plans that drive profitability, as well as, finance and corporate governance, further strengthening the company's commitment to driving growth while focusing on sustainable profitability. "We are thrilled to welcome Shmulik to our Board of Directors," said Oren Shuster, Chief Executive Officer of
SC 13G - IM Cannabis Corp. (0001792030) (Subject)
SC 13D/A - IM Cannabis Corp. (0001792030) (Subject)
SC 13G/A - IM Cannabis Corp. (0001792030) (Subject)
TORONTO and GLIL YAM, Israel, Nov. 13, 2025 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ:IMCC), an international medical cannabis company, announced its financial results today for the third quarter and nine months ended September 30, 2025. All amounts are reported in Canadian dollars and compared to the quarter and nine months ended September 30, 2024, unless otherwise stated. Q3 2025 Financial Highlights: Consistent Revenue for Q3 2025 and 2024 of $13.9 million.13% Gross profit decrease vs. Q3 2024 of $2.7 million vs. $3.1 million.13% Gross Margin decrease vs. Q3 2024 of 20% vs. 23%. $3.1 million One time goodwill and intangible asset impairment in Q3 2025 Operating
TORONTO and GLIL YAM, Israel, Aug. 13, 2025 /PRNewswire/ -- IM Cannabis Corp. ("IM Cannabis" or the "Company") (NASDAQ:IMCC), a leading medical cannabis company with operations in Israel and Germany, announces that it has agreed with holders (each, a "Holder") of common share purchase warrants ("November 2024 Warrants") issued by the Company as part of its non-brokered private placement offering which closed on November 12, 2024 to: (x) reduce the exercise price of each November 2024 Warrant from C$4.32 to C$3.43; and (y) extend the expiration date of each November 2024 Warrant from November 12, 2026 to July 31, 2030 (together, the "Transaction"). Form F-3 Resale Registration Statement The
IMC Delivers Strong Profit and Margin Growth Despite Revenue Impact from External Challenges in Q2 2025 TORONTO and GLIL YAM, Israel, Aug. 12, 2025 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ:IMCC), an international medical cannabis company, announced its financial results today for the second quarter ended June 30, 2025. All amounts are reported in Canadian dollars and compared to the quarter ended June 30, 2024, unless otherwise stated. Q2 2025 Financial Highlights 14% Revenue decrease vs. Q2 2024 of $12.7M vs. $14.8M 306% Gross profit increase vs.